← Home / Immuneering Corporation (IMRX)
Stock Analysis
Immuneering Corporation (IMRX)
IMRX
IMRX · Market data
4.13 -2.36%
Track IMRX in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when IMRX price is:
52W Range Position
18%
LOWMIDHIGH
Trend
Vulnerable
Momentum
Neutral
Updated: 2026-08-02 16:44 UTC
WOI Investment Thesis
Vulnerable
Watch confirmation and invalidation levels before acting.
⚖️
✓
Fundamentals
Insufficient / Insufficient
✓
Price Structure
Vulnerable
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
—
↗
Break Above
Confirmation improves above resistance.
4.67
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below —
Recent Company Events
SEC VERIFIED
Latest material filings
JUN
15
●
Management / Board
MEDIUM
IMRX board and management update
On June 11, 2026, the Board of Directors (the “Board”) of Immuneering Corporation (the “Company”) appointed Andrew Gengos as th e Chief Financial Officer and Treasurer of t he Company, to become effective on the commencement of his employment with the Company, which is expected to be on or before July 16, 2026 (the...
8-K Filing • SEC EDGAR
MAY
15
●
Financial Results
HIGH
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today reported financial results for the first quarter ended March 31, 2026, and provided business updates.
8-K Filing • SEC EDGAR
What's Driving IMRX?
📈 Technical recovery is improving
Momentum is Neutral. Watch 4.67 for confirmation and — for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
—
Full Analysis Workspace
Technical Signal
Waiting for Confirmation
▲
No confirmed breakout yet. Watch the next level and momentum behavior.
RSI(14)
37.9
Price Chart
IMRX — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-31
Spec
Speculative premium
Valuation is very demanding relative to current fundamentals; expectations are high.
Market Cap
$267.0M
Company size
EV
$219.7M
Debt-adjusted value
P/E
-4.9
Not meaningful
P/B
1.3
Low book multiple
EV/EBIT
-3.7
Not meaningful
P/FCF
-5.4
Not meaningful
FCF Yield
-18.69%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial context is mixed
Financial conditions require selective monitoring.
↗
Revenue Growth
Insufficient
●
Profitability
Insufficient
≈
Cash Flow
Pressured
⚖
Balance Sheet
Strong
💵 Revenue
0.00
≈ Insufficient
📈 Net Income
-13.46M
≈ Insufficient
🧮 EPS (Basic)
-0.21
≈ Insufficient
Immuneering Corporation
Related Opportunities